IT1392238B1 - USE OF CASPASI-3 FOR ALZHEIMER DISEASE - Google Patents

USE OF CASPASI-3 FOR ALZHEIMER DISEASE

Info

Publication number
IT1392238B1
IT1392238B1 ITRM2008A000641A ITRM20080641A IT1392238B1 IT 1392238 B1 IT1392238 B1 IT 1392238B1 IT RM2008A000641 A ITRM2008A000641 A IT RM2008A000641A IT RM20080641 A ITRM20080641 A IT RM20080641A IT 1392238 B1 IT1392238 B1 IT 1392238B1
Authority
IT
Italy
Prior art keywords
caspasi
alzheimer disease
alzheimer
disease
Prior art date
Application number
ITRM2008A000641A
Other languages
Italian (it)
Inventor
Amelio Marcello D
Virve Cavallucci
Original Assignee
Fond Santa Lucia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Santa Lucia filed Critical Fond Santa Lucia
Priority to ITRM2008A000641A priority Critical patent/IT1392238B1/en
Publication of ITRM20080641A1 publication Critical patent/ITRM20080641A1/en
Application granted granted Critical
Publication of IT1392238B1 publication Critical patent/IT1392238B1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
ITRM2008A000641A 2008-12-02 2008-12-02 USE OF CASPASI-3 FOR ALZHEIMER DISEASE IT1392238B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ITRM2008A000641A IT1392238B1 (en) 2008-12-02 2008-12-02 USE OF CASPASI-3 FOR ALZHEIMER DISEASE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2008A000641A IT1392238B1 (en) 2008-12-02 2008-12-02 USE OF CASPASI-3 FOR ALZHEIMER DISEASE

Publications (2)

Publication Number Publication Date
ITRM20080641A1 ITRM20080641A1 (en) 2010-06-03
IT1392238B1 true IT1392238B1 (en) 2012-02-22

Family

ID=41182632

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2008A000641A IT1392238B1 (en) 2008-12-02 2008-12-02 USE OF CASPASI-3 FOR ALZHEIMER DISEASE

Country Status (1)

Country Link
IT (1) IT1392238B1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542261A (en) * 1999-04-15 2002-12-10 メルク フロスト カナダ アンド カンパニー Antibody recognizing APP cleaved by caspase and use thereof
WO2001027085A1 (en) * 1999-10-13 2001-04-19 Merck Frosst Canada & Co. Nicotinyl aspartyl ketones as inhibitors of caspase-3
AU2002215766A1 (en) * 2000-12-15 2002-06-24 Merck Frosst Canada And Co. Gamma-ketoacid dipeptide derivatives as inhibitors of caspase-3
US20040058367A1 (en) * 2001-02-23 2004-03-25 Hideki Matsui Casoase 3 inhibitors
US8013014B2 (en) * 2002-07-05 2011-09-06 Georgia Tech Research Corporation Aza-peptide epoxides
EP1605893A4 (en) * 2003-03-05 2008-08-13 Innexus Biotechnology Inc Trans-membrane-antibody induced inhibition of apoptosis
US7326540B2 (en) * 2003-03-14 2008-02-05 The General Hospital Corporation Methods for identifying compounds that modulate stabilization of secretase-associated proteins
JP4885122B2 (en) * 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Proteolytic markers as diagnostic biomarkers for cancer, organ injury, and muscle rehabilitation / exercise overtraining

Also Published As

Publication number Publication date
ITRM20080641A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
CY2018030I2 (en) PHARMACEUTICAL FORM 514
SMT201500206B (en) Spiro-oxindolic compounds and their use as therapeutic agents
BRPI0916931A2 (en) therapeutic agents
ES2411907T8 (en) Therapeutic use of TWEAK anti-receptor antibodies
MA30948B1 (en) MYRTILLE NAMES "DrisBlueThree"
MA30949B1 (en) MYRTILLE NAMES "DrisBlueTwo"
NO20055643D0 (en) Preparation of lodixanol
BRPI0914533A2 (en) "methods"
FI20080580A (en) Arrangement for fixing the base to the wall
SMT201600041B (en) THERAPEUTIC AGENTS 713
DK2271321T3 (en) Pharmaceutical Composition 271
DE602007001830D1 (en) Preparation of borohydride salts
ITMI20061848A1 (en) PROCEDURE FOR THE PREPARATION OF PHENYLTETRAZOLIC COMPOUNDS
BRPI0908756A2 (en) Combined use of cholestanol derivative
ITRM20080546A1 (en) GINNICA CHAIR FOR THE STIMULATION OF THE MUSCLE-SKELETAL APPARATUS
BRPI0907797A2 (en) New use of 3,3'-diindolimethane
BRPI0913709A2 (en) "pharmaceutical formulation"
MA30860B1 (en) MYRTILLIER DENOMME "C97-390"
FR2933339B1 (en) SUPPORT STRUCTURE OF A COMBINED INSTRUMENT
IT1393508B1 (en) DICARBA-ANALOGHI DELL'OCTREOTIDE
BRPI0912535A2 (en) preparation of intermediates useful in the synthesis of 2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosylcytosine
IT1397508B1 (en) PROCEDURE TO ADJUST AN EXCITED SWING
IT1392238B1 (en) USE OF CASPASI-3 FOR ALZHEIMER DISEASE
IT1397522B1 (en) USE OF A COMBINATION FOR THE TREATMENT OF OSTEOARTROSI
ITRM20060440A1 (en) USE OF THE NIFEDIPINE FOR ANTI-WRINKLE TREATMENT